Compare Centene Corp (CNC) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs JPMorgan Chase & Co — how do they compare? Centene Corp trades at $66.91 (market cap $33.93B), while JPMorgan Chase & Co trades at $347.21 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 26.9× Centene Corp's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| CNC | JPM | |
|---|---|---|
Market Cap | $33.93B | $911.47B |
Sector | Health | Financials |
52-Week High | $68.72 | $342.89 |
52-Week Low | $25.21 | $282.84 |
Enterprise Value | $26.56B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene Corporation (CNC) trades at $68.29, up 1.4% with strong technical momentum and bullish moving average signals. The stock shows impressive 66% YTD gains, supported by recent contract renewals and margin recovery initiatives. Despite negative 2025 net income of -$6.67B, valuation metrics remain attractive with P/E of 8.06 and P/S of 0.17. Analyst consensus is strongly bullish with 61% buy ratings and $66.07 price target.
Centene presents a compelling value opportunity with low valuation multiples and strong operational cash flow of $5.09B. Key risks include ongoing margin pressure and Medicaid contract dependency. The company's AI-driven cost controls and recent Illinois Medicaid renewal provide catalysts for earnings recovery, though healthcare regulatory changes remain a concern for long-term stability.
JPMorgan Chase (JPM) trades at $347.22, up 3.79% on the day, with a bullish technical outlook and strong institutional support. The stock shows robust fundamentals with a 31.61% net income margin and 17.03% ROE, though Q4 2025 EPS missed expectations. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 2026 earnings, with analysts projecting a consensus price target of $377.75. Cash flow trends indicate significant investing outflows balanced by financing inflows.
JPM offers a solid investment case with attractive valuation (P/E 14.69) and analyst consensus leaning buy (51.67%), but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. The stock's proximity to its 52-week high suggests limited near-term upside, requiring careful monitoring of Q1 earnings results and macroeconomic indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
